Details:

Alternative Title:
MMWR. Morbidity and mortality weekly report
Description:
Herpes zoster vaccine (Zostavax, Merck & Co., Inc.) was licensed and recommended in 2006 for prevention of herpes zoster among adults aged 60 years and older. In March 2011, the Food and Drug Administration (FDA) approved the use of Zostavax in adults aged 50 through 59 years. In June 2011, the Advisory Committee on Immunization Practices (ACIP) declined to recommend the vaccine for adults aged 50 through 59 years and reaffirmed its current recommendation that herpes zoster vaccine be routinely recommended for adults aged 60 years and older.
Subject:
[+]
Herpes Zoster
Herpes Zoster Vaccine
Humans
Licensure
Middle Aged

Source:
MMWR. Morbidity and mortality weekly report. 2011 ; 60(44):1528.;
Pubmed ID:
22071592
Document Type:
Journal Article ;
Name as Subject:
United States. Food and Drug Administration. ;
Place as Subject:
United States ;
Collection(s):
Guidelines and Recommendations
Main Document Checksum:
[+]
urn:sha256:e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855
File Type:

Supporting Files

• No Additional Files

More +